Variates | Value |
---|---|
Cases of patients | 1453 |
Age, median (range) | 44.8 ± 11.9, 46 (15–88) |
Sex, male/female, number (%) | 368/1085 (25.3/74.7) |
Primary tumor size, median (mm) | 11.1 ± 7.2, 8.0 (0.1–55.0) |
PTMC/non-PTMC, number (%) | 863/590 (59.4/40.6) |
LN involvement, pN0/ pN1a/ pN1b, number (%) | 581/698/174 (40.0/48.0/12.0) |
total checked number of LNs ≥ 5/ < 5 among pN1patients | 694/178(79.6/20.4) |
NMLNs among pN1patients with a total checked number of LNs ≥ 5, NMLNs ≤ 5/ NMLNs > 5, number (%) | 472/222 (68.0/32.0) |
CLNs among pN1patients with a total checked number of LNs ≥ 5, CLNs ≤ 5/ > 5, number (%) | 535/159 (75.7/24.3) |
LLNs among pN1patients with a total checked number of LNs ≥ 5, LLNs ≤ 5/ > 5, number (%) | 624/70(89.9/10.1) |
Bilaterality, number (%) | 407 (28.0) |
Multifocality, number (%) | 531 (36.5) |
ETE /without ETE, number (%) | 1046/407 (72.0/28.0) |
TNM stage, I/II, number (%) | 1304/149 (89.7%/10.3%) |
BRAFV600E mutation, positive/negative/unknown, number (%) | 143/30/1280 (9.8/2.1/88.1) |
HT, number (%) | 196 (13.5) |
Duration of follow up (months) | 4–42 (22) |